Camp4 Therapeutics Corp Cash Flow Statement
CAMP|2 years of annual SEC 10-K data (FY2024-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 2 fiscal years. All figures from audited SEC 10-K filings.
Camp4 Therapeutics Corp used $30M in operating cash flow and negative free cash flow of $30M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -2.57 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 |
|---|---|---|
| Net Income | -$80.4M | -$49.3M |
| Depreciation & Amortization | $1.6M | $1.7M |
| Operating Cash Flow | -$29.6M | -$44.2M |
| Capital Expenditures | $279.0K | $678.0K |
| Free Cash Flow | -$29.8M | -$44.8M |
| FCF Margin | -852.8% | -12809.4% |